News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Innovus Pharma Readies the Launch of EjectDelay™ for Premature Ejaculation With Nationwide Sampling Program to Urologists in the U.S. Through the American Urology Association


9/24/2013 9:32:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LA JOLLA, Calif., Sept. 24, 2013 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company") www.innovuspharma.com (OTCBB:INNV) today announced that the Company will initiate a nationwide sampling of its topical benzocaine-based premature ejaculation FDA OTC compliant product EjectDelay through the American Urology Association's ("AUA") sampling program. Pursuant to the sampling program, each of the approximately 9,000 urologists in the U.S. will be receiving two samples of the product. The Company anticipates the sampling program to be completed within six to eight weeks.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES